The Shyft Group to Showcase Innovation and Customer-Centric Solutions at Work Truck Week 2024
Advanced work truck solutions highlight the collective expertise of Shyft’s diverse brand portfolio CEO John Dunn to present latest advancements […]
Progyny, Inc. Announces Share Repurchase Program
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health […]
Agrify Corporation Announces $3.4 Million Sales Order From New Jersey Woman-Owned Business HarvestWorks Farm
TROY, Mich., Feb. 29, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of […]
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase […]
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio […]
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives […]
Xos, Inc. Secures Purchase Order from Mission Linen Supply for New 22’ Stepvan Option
LOS ANGELES, Feb. 29, 2024 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS), a leading provider of medium-duty electric vehicles, charging […]
Xometry Reports Fourth Quarter and Full Year 2023 Results
Q4 revenue increased 31% year-over-year to $128 million driven by strong, accelerated marketplace growth of 42% year-over-year. Supplier services revenue […]
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies […]
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth […]
